Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Biotek-snakken
  4. Biotek-snakken — August 2024

Biotek-snakken — August 2024

Planlagt Fastgjort Låst Flyttet Biotek-snakken
113 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • HenrikhotH Offline
    HenrikhotH Offline
    Henrikhot
    wrote on sidst redigeret af
    #97

    Infant Bacterial Therapeutics AB (publ), Interim report January 1 – June 30, 2024 https://storage.mfn.se/e4463f81-0644-4c84-87fa-25f773e47ef8/ibt-q2-2024-eng.pdf

    1 Reply Last reply
    0
    • HenrikhotH Offline
      HenrikhotH Offline
      Henrikhot
      wrote on sidst redigeret af
      #98

      IBT has announced the crucial results from the global clinical phase 3 study “The Connection Study” for our drug project IBP-9414 are expected in Q3 2024.

      1 Reply Last reply
      0
      • HenrikhotH Offline
        HenrikhotH Offline
        Henrikhot
        wrote on sidst redigeret af
        #99

        This spring, the regulatory work began to prepare IBT's drug application for IBP-9414. The work has intensified, and more sections are ready. As soon as we have received results from “The Connection Study” IBT intends to contact the FDA and discuss how they want us to submit our data with the objective of reaching the market as soon as possible

        1 Reply Last reply
        0
        • F Offline
          F Offline
          Fandel
          wrote on sidst redigeret af
          #100

          Godmorgen...

          1 Reply Last reply
          0
          • L Offline
            L Offline
            LP90
            wrote on sidst redigeret af
            #101

            Godmorgen 🙂

            1 Reply Last reply
            0
            • F Offline
              F Offline
              Fandel
              wrote on sidst redigeret af
              #102

              Godmorgen...

              1 Reply Last reply
              0
              • L Offline
                L Offline
                LP90
                wrote on sidst redigeret af
                #103

                Godmorgen 🙂

                1 Reply Last reply
                0
                • exitnuE Offline
                  exitnuE Offline
                  exitnu
                  wrote on sidst redigeret af
                  #104

                  God morgen 🙂

                  1 Reply Last reply
                  0
                  • exitnuE Offline
                    exitnuE Offline
                    exitnu
                    wrote on sidst redigeret af
                    #105

                    Er gået med mht. Ascelia Pharma / pengene er allerede trukket hos SAXO 🙂

                    1 Reply Last reply
                    0
                    • exitnuE Offline
                      exitnuE Offline
                      exitnu
                      wrote on sidst redigeret af
                      #106

                      Penser Access & Future by Carnegie: Ascelia Pharma: Höjdpunkter från Carnegies Småbolagsdag 2024

                      Ascelia Pharma presentation - Carnegie småbolagsdag:

                      1 Reply Last reply
                      0
                      • exitnuE Offline
                        exitnuE Offline
                        exitnu
                        wrote on sidst redigeret af
                        #107

                        Höjdpunkter från presentationen

                        Bolagets VD Magnus Corfitzen deltog igår på Carnegies Småbolagsdag 2024. Presentationen innehöll inga större överraskningar och sammanfattade utvecklingsläget i bolagets huvudprojekt Orviglance och Oncoral. Vi förväntar oss den fullständiga datautläsningen av SPARKLE-studien under Q4(24).

                        1 Reply Last reply
                        0
                        • exitnuE Offline
                          exitnuE Offline
                          exitnu
                          wrote on sidst redigeret af
                          #108

                          Nästa steg för Orviglance blir nu att arbeta med att ta fram en marknadsansökan till regulatoriska myndigheter, vilket bolaget bedömer kommer kunna skickas in under mitten av 2025. Detta skulle implicera ett potentiellt marknadsgodkännande för Orviglance under 2026

                          1 Reply Last reply
                          0
                          • exitnuE Offline
                            exitnuE Offline
                            exitnu
                            wrote on sidst redigeret af
                            #109

                            Xbrane Biopharma Q2 2024: A fight against the clock

                            Just a moment...

                            favicon

                            (www.redeye.se)

                            1 Reply Last reply
                            0
                            • F Offline
                              F Offline
                              Fandel
                              wrote on sidst redigeret af
                              #110

                              Godmorgen...

                              1 Reply Last reply
                              0
                              • R Offline
                                R Offline
                                Rasbom
                                wrote on sidst redigeret af
                                #111

                                IBT misser first endpoint. Men viser significant effekt i dødelighed og søger om registrering hos FDA.

                                1 Reply Last reply
                                0
                                • exitnuE Offline
                                  exitnuE Offline
                                  exitnu
                                  wrote on sidst redigeret af
                                  #112

                                  IBT’s phase III study shows no significant effects on the primary endpoints but a significant reduction in the secondary endpoint, all-cause mortality (August 30, 2024)

                                  Link Preview Image
                                  IBT | IBT’s phase III study shows no significant effects on the primary endpoints but a significant reduction in the secondary endpoint, all-cause mortality

                                  favicon

                                  (ibtherapeutics.com)

                                  (nu med link)

                                  1 Reply Last reply
                                  0
                                  • exitnuE Offline
                                    exitnuE Offline
                                    exitnu
                                    wrote on sidst redigeret af
                                    #113

                                    Infant Bacterial Therapeutics fase III-studie

                                    Link til uddybende debat:

                                    Just a moment...

                                    favicon

                                    (proinvestor.com)

                                    1 Reply Last reply
                                    0
                                    • P Offline
                                      P Offline
                                      ProinvestorNEWS
                                      wrote on sidst redigeret af
                                      #114

                                      IO Biotech's Phase 3 Trial Data Fails To Show Superiority In ORR For IO102-IO103 With KEYTRUDA https://proinvestor.com/investornyt/1207657/io-biotechs-phase-3-trial-data-fails-to-show-superiority-in-orr-for-io102-io103-with-keytruda

                                      1 Reply Last reply
                                      0

                                      Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                      Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                      With your input, this post could be even better 💗

                                      Tilmeld Log ind
                                      Svar
                                      • Svar som emne
                                      Login for at svare
                                      • Ældste til nyeste
                                      • Nyeste til ældste
                                      • Most Votes


                                      • Log ind

                                      • Har du ikke en konto? Tilmeld

                                      • Login or register to search.
                                      Powered by NodeBB Contributors
                                      • First post
                                        Last post
                                      0
                                      • Kategorier
                                      • Seneste
                                      • Etiketter
                                      • Populære
                                      • Verden
                                      • Bruger
                                      • Grupper